Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Novo Nordisk A/S9 enrolled

Overview

This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Congenital Bleeding Disorder Haemophilia A With Inhibitors Haemophilia B With Inhibitors

Interventions

eptacog alfa (activated)DRUG

Prescription of eptacog alpha at the discretion of the physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Treated with eptacog alpha (NovoSeven®) Exclusion Criteria: * Investigator decision to measure for antibody as unnecessary medical testing

Locations (1)

Novo Nordisk Investigational Site

Tokyo, Japan

Outcomes

Primary Outcomes

Antibody production against eptacog alpha

Time frame: Up to 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.